Recent News Stories Shows How The Australian Migraine Drugs Market Products Are Surviving In The Global Industry To 2028?

Report Overview

The Australian Migraine Drugs market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Migraine is a neurological condition that is estimated to affect 4.9 million Australians. Migraine is characterized by recurrent attacks of moderate to severe headache. Migraine pain is typically pulsating, affecting one side or area of the head. During a migraine attack, patients may experience nausea, vomiting, and sensory sensitivity such as phonophobia and photophobia that significantly affects their lives. Despite its impact, migraine is underdiagnosed and undertreated. The total economic costs of migraines in 2018 are estimated to be $35.7 billion in 2018. $8.1 billion (23%) of these costs are attributable to chronic migraine and $27.6 billion (77%) are attributable to episodic migraine.

Market Drivers

The rise in prevalence of migraine and the development of novel drugs are the major drivers which propelled the demand of the market in the forecast period. The rising population and growing demand for quality drugs are significant factors driving the growth of the global migraine drugs market. Creating awareness over the availability of different treatment procedures for migraines in rural areas boosts the demand of the market. Investments in the development of new drugs by market players and other companies are also leveling up the growth rate of the market. Changes in lifestyles and rising stress levels among people are some of the factors for the market to grow.

Epidemiology

20.55% of Australians suffer from migraines. Prevalence is higher for women, with 28.66% of women experiencing migraines compared to 11.96% of men (Institute for Health Metrics Evaluation (IHME), 2016). 7.6% of Australian migraine sufferers experience a severe form of migraine known as chronic migraine, defined as 15 or more migraine days per month.

Females aged 25 to 29 face the highest prevalence rate of chronic migraine (3.7% of this cohort), while the highest prevalence rate of episodic migraine (42.3%) occurs in females aged 35 to 39. Migraine prevalence (rate and cases) is higher among females than males in every age group, and prevalence (rate and cases) for males is more stable across age groups. 86% of people with migraines are of working age (15-65).

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/140018/

Major Players

Migraine treatment market competitive landscape provides details by the competitor. The major players covered in the report are Amgen Inc., Eli Lilly, and Company, GlaxoSmithKline plc., Novartis AG, Bayer AG, Allergan, Abbott, AstraZeneca, Bausch Health Companies Inc, Catalent, Inc, Dr. Reddy's Laboratories Ltd., Lundbeck, Merck Sharp & Dohme Corp (A Subsidiary of Merck & Co., Inc.), Pfizer Inc., Otsuka Pharmaceutical Co., Ltd (A Subsidiary of Otsuka Holdings Co., Ltd.), Sun Pharmaceutical Industries Ltd, among others.

In November 2019, REYVOW a product developed by Eli Lily and company has received FDA approval for acute migraine treatment. This product approval has increased the company's solution for migraine treatment and hence helped it to enhance its revenue by increasing its product sales.

The Australian Migraine Drugs Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Australian Migraine Drugs market. This report explores all the key factors affecting the growth of the global Australian Migraine Drugs market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

To Know More About COVID-19 Impact On Australian Migraine Drugs Market @ https://www.prudentmarkets.com/sample-request/140018/

Market Segmentation

By Drug Class:

Based on drug class, the Australian migraine drugs market is segmented into abortive medicine (which is further sub-segmented into triptans, ergots, and others) and preventive medicines which is further sub-segmented into anticonvulsant, antidepressant, beta-blockers, and others). Triptans are a class of medications used to treat acute migraine attacks - that is, the part of your migraine attack where symptoms are most severe, for many people the headache part of the attack. Acute medications are designed to stop a migraine attack as the attack begins. Triptans cannot prevent your attack but can help alleviate the symptoms of migraine attacks such as pain, nausea, and sensitivity to light and sound.

By Route of Administration:

Based on the route of administration, the market is segmented into oral, parenteral, and others. An oral segment is expected to dominate the market as most of the available drugs used for migraine treatment are available in tablet forms, as oral route is used most often as it is considered safest, convenient, and least expensive.

By Distribution Channel:

Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment is expected to dominate the market as hospitals are the primary source from where drugs can be procured by patients.

Major Players

Migraine treatment market competitive landscape provides details by the competitor. The major players covered in the report are Amgen Inc., Eli Lilly, and Company, GlaxoSmithKline plc., Novartis AG, Bayer AG, Allergan, Abbott, AstraZeneca, Bausch Health Companies Inc, Catalent, Inc, Dr. Reddy's Laboratories Ltd., Lundbeck, Merck Sharp & Dohme Corp (A Subsidiary of Merck & Co., Inc.), Pfizer Inc., Otsuka Pharmaceutical Co., Ltd (A Subsidiary of Otsuka Holdings Co., Ltd.), Sun Pharmaceutical Industries Ltd, among others.

In November 2019, REYVOW a product developed by Eli Lily and company has received FDA approval for acute migraine treatment. This product approval has increased the company's solution for migraine treatment and hence helped it to enhance its revenue by increasing its product sales.

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/140018/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global Australian Migraine Drugs Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global Australian Migraine Drugs Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Australian Migraine Drugs market
Chapter 2: Exclusive Summary - the basic information of the Australian Migraine Drugs Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Australian Migraine Drugs
Chapter 4: Presenting the Australian Migraine Drugs Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the Australian Migraine Drugs market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/140018/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the Australian Migraine Drugs Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.